Takeda-6D

• Description :

  Takeda-6D (compound 6d) is an orally active and potent BRAF/VEGFR2 inhibitor, with IC50 values of 7.0 and 2.2 nM, respectively. Takeda-6D shows antiangiogenesis by suppressing the VEGFR2 pathway in 293/KDR and VEGF-stimulated HUVEC cells.Takeda-6D shows significant suppression of ERK1/2 phosphorylation. Takeda-6D shows antitumor activity[1].

• UNSPSC :

  12352005

• Target :

  PERK; Raf; VEGFR

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/takeda-6d.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(NC1=CC(OC2=CC=C3C(SC(NC(C4CC4)=O)=N3)=N2)=CC=C1F)C5=CC=CC(C6(C#N)CC6)=C5Cl

• Molecular Formula :

  C27H19ClFN5O3S

• Molecular Weight :

  547.99

• References & Citations :

  [1]Okaniwa M, et al. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds. J Med Chem. 2012 Apr 12;55 (7) :3452-78.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  B-Raf; VEGFR2/KDR/Flk-1

• CAS Number :

  [1125632-93-0]